Debt-to-equity of Aligos Therapeutics, Inc. from 30 Jun 2021 to 31 Dec 2025

Taxonomy & unit
ratio: %
Description
Debt-to-equity (D/E) ratio is used to evaluate a company's financial leverage and is calculated by dividing a company's total liabilities by its shareholder equity.
Summary
Aligos Therapeutics, Inc. quarterly Debt-to-equity in % history and change rate from 30 Jun 2021 to 31 Dec 2025.
  • Aligos Therapeutics, Inc. Debt-to-equity for the quarter ending 31 Dec 2025 was 41%, a 76% decline year-over-year.
Debt-to-equity, Quarterly (%)
Debt-to-equity, YoY Quarterly Change (%)

Aligos Therapeutics, Inc. Quarterly Debt-to-equity (%)

Period Value YoY Chg Change % Date
Q4 2025 41% -126% -76% 31 Dec 2025
Q3 2025 78% +1.1% +1.4% 30 Sep 2025
Q2 2025 85% +12% +17% 30 Jun 2025
Q1 2025 104% +34% +47% 31 Mar 2025
Q4 2024 167% +112% +206% 31 Dec 2024
Q3 2024 77% +30% +64% 30 Sep 2024
Q2 2024 73% +31% +76% 30 Jun 2024
Q1 2024 71% +33% +89% 31 Mar 2024
Q4 2023 54% +18% +49% 31 Dec 2023
Q3 2023 47% +14% +43% 30 Sep 2023
Q2 2023 42% +13% +44% 30 Jun 2023
Q1 2023 37% +10% +37% 31 Mar 2023
Q4 2022 36% +13% +56% 31 Dec 2022
Q3 2022 33% +11% +51% 30 Sep 2022
Q2 2022 29% -10% -26% 30 Jun 2022
Q1 2022 27% 31 Mar 2022
Q4 2021 23% 31 Dec 2021
Q3 2021 22% 30 Sep 2021
Q2 2021 39% 30 Jun 2021
* An asterisk sign (*) next to the value indicates that the value is likely invalid.